TPTX - Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study

Turning Point Therapeutics (TPTX) announces updated interim findings from the ongoing TRIDENT-1 study of repotrectinib in patients with ROS1-positive TKI-naïve non-small cell lung cancer ((NSCLC)). In a total of 15 patients enrolled in Phase 2 portion, confirmed objective response rate ((ORR)) was 93% (95% CI: 68-100).In 22 patients pooled from the Phase 1 and Phase 2 portions, the confirmed ORR was 91% (95% CI: 71-99).Repotrectinib was generally well tolerated.The company plans to conduct Type B meeting with the FDA in H1 2021 to discuss regulatory path.

For further details see:

Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study